GlobeNewsWire
03 Aug 2026, 11:40 UTC · 6w ago
Verdict
Headline takes no side. We score HELP +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 83% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Helus Pharma expects topline data from its first pivotal Phase 3 study (APPROACH) for HLP003 in the treatment of Major Depressive Disorder in Q4 2026.
So whatTopline Phase 3 results are the primary binary catalyst for clinical-stage biotech valuations.
More positive than 92% of claims this week
Helus Pharma appointed Michael Halstead, former President of Intra-Cellular Therapies, as CEO.
So whatHalstead has a proven track record of scaling a similar CNS company and overseeing a $14.6 billion exit to Johnson & Johnson.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 76% of claims this week
Enrollment is complete for the APPROACH study, while enrollment continues for the second pivotal Phase 3 study, EMBRACE.
So whatCompletion of enrollment reduces execution risk and confirms the timeline for the Q4 data readout.
More positive than 49% of claims this week
Which stocks this story touches
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Reuters
3d ago
+58.2%
Price agrees with the score
$12.37 vs $7.82 close before publication (Jul 31) · not market-adjusted
HELP chart →
